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Background and current status
Every living cell in nature that has emerged from more than 3 bil-
lion years of biological evolution is composed of nucleic acids, 
proteins, lipids, metabolites, and glycans, and each of these com-
ponents remains essential to all life forms. Until the 1970s, the 
study of glycans was thus an integral part of the exploration of all 
biological systems, generating major advances in fields as diverse 
as hematology, microbiology, metabolism, and material sciences. 
With the rapid advent of powerful insights and tools, the study of 
nucleic acids and proteins came to dominate the molecular biol-
ogy revolution of subsequent decades. While similar revolutions in 
the biological exploration of lipids and metabolites have now fol-
lowed, the study of glycans has been left far behind. The reasons 
for this omission are many, but can be broadly ascribed to the far 
greater complexity and diversity of this class of molecules and the 
related lack of comparable tools for their exploration. In analogy to 
the situation in cosmology, the “standard model” for approaching 
biological systems now largely excludes glycans, which have effec-
tively become the “dark matter” of the biological universe: criti-
This position statement originated from a working group meeting convened on April 15, 2015, by the NHLBI and incorporates 
follow-up contributions by the participants as well as other thought leaders subsequently consulted, who together represent 
research fields relevant to all branches of the NIH. The group was deliberately composed not only of individuals with a current 
research emphasis in the glycosciences, but also of many experts from other fields, who evinced a strong interest in being 
involved in the discussions. The original goal was to discuss the value of creating centers of excellence for training the next 
generation of biomedical investigators in the glycosciences. A broader theme that emerged was the urgent need to bring the 
glycosciences back into the mainstream of biology by integrating relevant education into the curricula of medical, graduate, 
and postgraduate training programs, thus generating a critical sustainable workforce that can advance the much-needed 
translation of glycosciences into a more complete understanding of biology and the enhanced practice of medicine.
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lic. Glycans are integral components of living organisms, 
whether human, animal, plant, or microbe, and glycan 
products have applications in health, energy, and materials 
science. The committee concludes that integrating glycosci-
ence into relevant disciplines in high school, undergraduate, 
and graduate education, and developing curricula and stan-
dardized testing for science competency would increase 
public as well as professional awareness.
Within 10 years, glycoscience will be integrated and 
taught at every level wherever it is relevant to understand 
the scientific content.
In response to the overall NRC report, the NIH Office of Stra-
tegic Coordination via the NIH Director’s Common Fund released 
a series of requests for applications with the following program 
initiatives: (a) developing methods and technologies for synthesis 
of biomedically relevant carbohydrates; (b) developing accessible 
tools for probing and analyzing carbohydrates and their interac-
tion partners; (c) developing data integration and analysis tools.
Notably lacking was any direct support for training in glycosci-
ences. It was the charge of this working group to consider further 
the need for mechanisms to address this unmet need.
Working group objectives
The working group defined its objectives as follows: “Discuss 
the value and mechanisms of training the next generation of 
biomedical investigators in the glycosciences, with the goal of 
bringing glycoscience back into the mainstream of biology — by 
generating a critical sustainable workforce that will advance the 
translation of glycosciences in biology and medicine, and help 
integrate glycoscience education into the curricula of medical 
and graduate schools” (1).
Definition of needs and opportunities
There is increasing recognition of the diverse roles and uses of 
glycans in biology and medicine. Yet glycoscience has not gained 
much attention in the mainstream of biology and is viewed as 
a niche research area with relatively few qualified researchers. 
While high school, undergraduate, and graduate students learn 
about nucleic acids, proteins, lipids, and metabolites, their com-
petency in understanding the chemistry and biology of glycans is 
now conspicuously deficient. Also, compared with the NIH invest-
ments made in understanding other major components of life, 
glycans have received very little attention. This chasm needs to be 
addressed by training a new generation of biomedical researchers 
for whom glycans are an integral part of their mainstream thinking.
The working group discussed the role of glycosciences in the 
discovery process. One theme that repeatedly arose was that the 
field is indeed poorly represented among researchers and lectur-
ers at most biomedical research institutions. Despite this, some 
great advances in biomedical discovery in several areas, including 
hematology, immunology, infectious diseases, genetic diseases, 
cancer, and neuroscience, have been facilitated by the coinciden-
tal proximity of key investigators to colleagues who understood 
the glycoscience aspects of their research and also had the motiva-
tion and tools to apply this understanding to the biomedical chal-
lenges at hand. Without such serendipitous input, the discoveries 
cal for a full understanding of biology and yet routinely ignored. 
While a small number of scientists persisted in the in-depth study 
of glycans (resulting in a specialized field called glycobiology), an 
entire generation of mainstream biologists was trained with little 
knowledge of the structure, analysis, or functions of glycans or 
even of the terminology required for discussing them. This anom-
aly in the history of the biological sciences has since trickled down 
to all levels of education, resulting in lost opportunities for a more 
complete understanding of the biology and pathology of living sys-
tems, which would also greatly benefit therapeutic development 
and medical practice. Very few scientists are thus now trained in 
understanding glycosciences, and studies of glycans have also lost 
prominent attention from major journals and grant review groups 
or recognition by honors and awards.
Recognizing this stark deficiency, the NIH, the National Sci-
ence Foundation (NSF), the Department of Energy (DOE), the 
FDA, and the Howard Hughes Medical Institute (HHMI) com-
missioned an enquiry into the situation by the National Research 
Council (NRC) of the National Academies (1). The resulting 2012 
report, entitled Transforming Glycoscience: A Roadmap for the 
Future, noted the following:
Glycoscience is a highly interdisciplinary field that aims to 
better understand the structures and functions of glycans 
and how they can be used. It is a global field with a dedi-
cated community of researchers in the United States and 
abroad. Glycoscientists do not have a single training/edu-
cation background. They come from various fields, includ-
ing physiology and developmental biology, where glycans 
are involved in processes such as cell movement and tis-
sue development. They are in medicine, where glycans are 
involved in the development and progression of chronic and 
infectious diseases. In microbiology, glycans are key players 
in interactions among and between microbes and host cells. 
Glycoscientists are chemists developing new synthetic and 
analytical methods for glycans, and biochemists working to 
understand glycan synthesis and metabolism. In materials 
science, glycans can be used as polymeric materials having 
a wide range of properties. In computational science and 
informatics, modeling studies and the effective analysis of 
large amounts of experimental data are also necessary to 
better understanding glycans.
In the area of human health, the NRC report also noted that 
(a) glycans are directly involved in the pathophysiology of every 
major disease; (b) additional knowledge from glycosciences will 
be needed to realize the goals of personalized medicine and to 
take advantage of the substantial investments in human genome 
and proteome research; and (c) glycans are increasingly important 
in pharmaceutical development.
Among the resulting roadmap goals in the NRC report were 
specific comments and recommendations regarding enhanced 
training in the glycosciences.
The committee notes that there is widespread lack of under-
standing and appreciation of glycoscience in the scientific 
and medical communities and among the general pub-
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developed to target glycan-binding sites on functional glycan-
binding proteins are now showing promise for syndromes such 
as sickle cell crises, with more under development by the biotech 
and pharmaceutical industries.
A consensus arose on the committee that the basic and thera-
peutic significance of glycosciences has already been well estab-
lished, with more progress on the way. But maintaining and accel-
erating translation in glycosciences will require a reversal of the 
ongoing year-over-year deficit of knowledge in this area among 
most biomedical scientists. One solution will be to populate major 
academic research centers, research institutes, government labo-
ratories, and drug development companies with colleagues who 
have experience and knowledge in the glycosciences. But the pool 
of such individuals is currently very small. Potential resources 
that will help correct this situation are discussed further below. In 
addition, we believe several key actions are required to bring more 
of our trainees and colleagues on board, as detailed in Building a 
workforce versed in glycoscience.
Developing resources for glycoscience training
It is the consensus of the working group that bottom-up rebuild-
ing of the glycoscience enterprise with a long-range perspective 
will enhance all aspects of biology and medicine. In particular, 
investing resources in populating the biomedical research enter-
prise at all levels with individuals trained in the discipline will 
have outsized positive effects on discovery. The presence of 
trained glycoscientists as researchers, faculty members, science 
administrators, reviewers, journal editors, biomedical inves-
tors, patent officers, and consultants will reverse the “glycosci-
ence desert” at many institutions and levels and begin to infuse 
would have been delayed or not been made at all. Furthermore, 
without knowledgeable faculty in many biomedical educational 
institutions, there is a striking absence of lectures and seminars in 
the area. This creates a feed-forward self-perpetuating deficit of 
knowledge in the field. Glycosciences are not taught (or are barely 
taught) at many institutions, leading to a generation of otherwise 
superbly trained physicians and biomedical scientists who are 
nonetheless unfamiliar with language and basic knowledge in this 
key aspect of all biological systems. When such individuals enter 
the biomedical workforce, whether in academia, science adminis-
tration, or the drug discovery and diagnostics industries, they are 
unlikely to grasp the implications of glycosciences for their own 
work or that of others. They are also unlikely to sufficiently empha-
size glycoscience training in the curricula they develop. Genera-
tion after generation, we are now losing ground with regard to the 
potential of this discipline.
For those few who do make glycosciences their career, the 
rewards of discovery are hard fought, often against significant 
resistance from editorial boards, grant review committees, and 
biomedical investment groups who lack the basic knowledge of 
glycosciences necessary to understand the goals and opportuni-
ties at hand. Despite these challenges, significant advances have 
been translated from glycoscience discovery to the clinic. For 
example, many groundbreaking biologicals now in the clinic, 
including cytokines, such as erythropoietin and all monoclonal 
antibodies, are glycoproteins that are expressly dependent on 
their glycans for pharmacodynamic and pharmacokinetic proper-
ties, stability, and function. Important vaccines have been devel-
oped based on microbial glycans, such as pneumococcus and hae-
mophilus polysaccharides. In addition, glycomimetic compounds 
Building a workforce versed in glycoscience
Add basic knowledge of glycoscience to national standardized tests to encourage inclusion of the discipline in teaching.
Include more key concepts of glycoscience in undergraduate and graduate level textbooks in the biomedical sciences (e.g., cell 
biology, biochemistry).
Encourage opportunities for hands-on training in glycoscience experimentation and discovery.
“Democratize” glycoscience for nonspecialists. Train life scientists and clinicians to be conversant in the discipline, even if they 
never become experts.
Encourage glycoscientists to seek opportunities to lecture outside of the field in order to disseminate knowledge, break down 
barriers, and motivate others to embrace glycoscience within their biomedical world view.
Integrate glycosciences in their appropriate place in all major chemical and biomedical disciplines, instead of as a field apart. 
Make glycobiology integral to biology and glycochemistry integral to biochemistry and organic chemistry.
Emphasize the attractive biological functional aspects of the field to motivate students and colleagues to delve more deeply into 
its details.
Promote existing resources (textbooks, online content) to help established faculty expand glycoscience teaching.
Leverage opportunities from successful pharmaceutical developments that have been highlighted online and in the popular 
press to emphasize positive outcomes arising from glycosciences.
Encourage training of those at regulatory and governmental bodies in the opportunities of glycosciences.
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to synthesize and analyze them. This is changing, with new capa-
bilities and new resources focused on enhancing research tools in 
glycosciences. While such investments are very worthwhile, they 
will fall short of their promise unless the stark deficit in training 
and knowledge in the field is vigorously addressed. The commit-
tee feels that using a bottom-up approach of emphasizing training 
and incentivizing an increased number of young investigators will 
begin to reverse the self-perpetuating underutilization of glyco-
sciences in biomedical sciences, resulting in outsized benefits 
towards enhancing knowledge and tools in the discipline and thus 
more effectively meeting the mandates of the NIH in particular 
and the biomedical research enterprise in general.
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knowledge about glycans into teaching, research, and the knowl-
edge base of physicians and scientists.
As demonstrated by the successes of the current NHLBI-
sponsored Programs of Excellence in Glycoscience mechanism, 
a quick way to achieve this goal in the short term is to develop 
programs of supervised research training to bring more young 
investigators at the postdoctoral and starting faculty level into the 
field. This type of intensive immersion training of those late in 
their training careers has been shown to have a significant posi-
tive outcome in keeping trainees in the field when they embark on 
independent careers. We propose that specific steps can be taken 
to address this gap for young investigators, as detailed in Expand-
ing support for glycoscience training.
Concluding statement
Glycans are ubiquitous in all living cells and organisms, where they 
serve essential functions, ranging from acting as structural compo-
nents to regulating physiological and pathological processes. Evi-
dence clearly indicates that glycans represent a largely untapped 
resource for biological discovery as well as unanticipated thera-
peutic opportunities. However, among the major classes of bio-
molecules, glycans have generally received the least attention, in 
part due to a self-perpetuating underappreciation of their biologic 
impact, their inherent structural complexity, and the lack of tools 
Expanding support for glycoscience training
Create centers of excellence for training the next generation of biomedical investigators in the glycosciences. As an example, 
establish new K12 and K01 mechanisms to support supervised transition of biomedical scientists late in training to inde-
pendent careers with full integration of the glycosciences. It is anticipated that such awards would incentivize established 
experts to recruit and mentor young colleagues and to expand the presence of independent glycoscience-knowledgeable 
investigators across the biosciences.
Provide independent support for those with recent glycoscience-related doctorates to pursue glycoscience-related postdoctoral 
research collaboratively in laboratories that are not traditionally glycoscience focused. This support will encourage those 
with glycoscience needs to access expertise and expand the knowledge base of their laboratories in this discipline.
Create a collaborative research award for a laboratory in need of glycoscience expertise to work with an established glycosci-
ence laboratory. This could perhaps take the form of supplements to existing R01 grants of the two labs in question. This 
mechanism should be considered by all NIH institutes whose portfolios are relevant to glycosciences.
Support fellowships for undergraduate and medical students to perform summer projects in glycoscience laboratories.
Encourage NIH institutes to include glycoscience training in the form of special-emphasis training grants.
Expand upon the few existing immersive glycoscience training courses to bring investigators who are not in the field up to speed 
in basic knowledge of glycosciences. A Gordon Conference or Wood’s Hole/Cold Spring Harbor–style week-long or multi-
week format, already successful in advanced glycoscience courses in Europe, could be a model. Multidisciplinary meetings 
or workshops emphasizing the roles of glycans in fields such as neuroscience, cancer, immunity, infectious diseases, blood 
and vascular systems, etc. would also be of value.
Encourage established glycoscientists to get more involved in basic undergraduate and graduate courses, ranging from organic 
chemistry to structural biology, physiology, and molecular and cellular biology.
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